Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 15.25
-2.74 %
$ 1.39 B
Market Cap
-11.91
P/E
Price Target
Average
96.72%
Revenue Forecast
Estimate
12.22%
EBIT
Estimate
0.14%
Net Income
Estimate
26.00%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Myriad Genetics, Inc.
Wall Street analysts predict an average 1-year price target for MYGN of $30 , with forecasts ranging from a low of $23 to a high of $35 .
MYGN Lowest Price Target
Wall Street Target
23 USD
50.82%
MYGN Average Price Target
Wall Street Target
30 USD
96.72%
MYGN Highest Price Target
Wall Street Target
35 USD
129.51%
REVENUE FORECAST
Revenue Forecast Chart MYGN
EBIT FORECAST
EBIT Forecast Chart MYGN
NET INCOME FORECAST
Net Income Chart MYGN